Background. Surgical-treatment outcomes for melanoma in African Americans are poorly characterized as a result of low incidence of melanoma among African Americans. We examined differences by race in overall and melanomaspecific survival, stratified by receipt of surgical treatment and by specific types of surgical treatment. Methods. Data from the 1973-2004 public-use Surveillance, Epidemiology and End Results Program (SEER) were analyzed by Cox proportional hazard models to compare the effects of surgical treatments on overall and melanoma-specific survival in blacks, whites, and other race, controlling for confounding demographic and tumorrelated variables. Results. Of 151,154 patients with first primary melanoma (148,883 whites, 789 blacks and 1,532 other race), 142,653 (94.4%) received surgical treatment. Among patients who received surgical treatment, 10-year melanoma-specific survival was lower in blacks (73%) than in whites (88%) and other race (85%); black patients were at significantly higher risk of overall and melanoma-specific mortality when compared with white (hazard ratio [HR] = 1.64, 95% confidence interval [CI] 1.44-1.86, P \ 0.0001 and HR = 1.50, 95% CI 1.25-1.79, P \ 0.0001, respectively) and with other race (HR = 1.55, 95% CI 1.31-1.85, P \ 0.0001 and HR = 1.49, 95% CI 1.16-1.91, P = 0.0017, respectively). Blacks who underwent biopsy, wide excision and surgery not otherwise specified were at higher risk of overall mortality compared with whites with the same treatment. Conclusion. Overall and melanoma-specific survival was lower in blacks undergoing surgical treatment for melanoma compared to both whites and other race. Reasons for these disparities remain poorly understood.
histological subtypes and to be diagnosed at advanced stages, portending a poor prognosis. 5, 8 The primary treatment for melanoma is surgical excision. Systemic adjuvant therapies and radiotherapy may be considered for patients with high risk melanomas, including those with lymph node involvement and distant metastases. [9] [10] [11] [12] [13] However, most systemic treatments have not been shown to improve survival, and survival is poor for regionally advanced (stage III) and metastatic (stage IV) melanoma. 10 To the authors' knowledge, this is the first large, population-based study to examine differences by race in overall and melanoma-specific survival, stratifying the analyses by receipt of surgical treatment and by specific types of surgical treatment while controlling for demographic and tumor-related factors. Given the increases in racial/ethnic minority populations in the United States, a better understanding of the impact of melanoma surgical treatment on survival in these patient populations is needed. 14 
METHODS

Public-use Surveillance, Epidemiology, and End Results
Program (SEER) data were used to conduct a retrospective, population-based cohort study of patients with a first primary diagnosis of cutaneous melanoma between January 1, 1973, and December 31, 2004 . To maximize the number of racial/ethnic minority patients with melanoma, data from all 17 SEER tumor registries were included in the analysis. 15 This study was approved by the institutional review board at Washington University.
Patients with a first primary cutaneous melanoma were identified by the SEER code 25010 and a sequence number 00, indicating only one primary malignancy in the patient's record. Patients were excluded if they had more than one record (indicating more than one cancer) or were diagnosed with melanoma after another cancer diagnosis or by death certificate or autopsy only.
Demographic variables included age at diagnosis, sex, race, and year of diagnosis. By using the SEER codes for race, three groups were created for analysis: white, black, and other race (including American Indian, Alaska Native, Asian, Pacific Islander and ''other unspecified''); 9582 patients whose race was coded as ''unknown'' were excluded. Because Hispanic ethnicity crosses all race codes in SEER, this variable was not included in the analysis.
Tumor-related variables included histologic subtype, SEER historic stage A, primary anatomic site, satellite nodules/tumors, skin ulceration and lymph node extension. Histologic subtypes for cutaneous melanoma were recorded by SEER according to the International Classification of Diseases for Oncology (ICD-O) codes. 16 The SEER histology codes were grouped for analysis as follows: in situ, nodular melanoma, lentigo maligna melanoma, superficial spreading melanoma, acral lentiginous melanoma, and malignant melanoma not otherwise specified (NOS). The latter category included a heterogeneous group of histological subtypes that did not fit in one of the first five categories and had too few cases to be analyzed separately (Appendix A 16 Primary anatomic site groupings included trunk, upper extremity, lower extremity, skin NOS, and head and neck.
Four SEER variables, ''satellite tumors' ' (1973-1982) , ''extension' ' (1983-2003) , and ''clinical stage (CS) lymph nodes'' (2004) were recoded to form a 3-category satellitenodule variable (having satellite nodules, not having satellite nodules, or unknown). Three SEER variables, ''type of melanoma '' (1973-1982) , ''extension' ' (1988-2003) and ''CS site specific factor 2 ulceration'' (2004), were used to form a 3-category skin-ulceration variable (having skin ulceration, not having skin ulceration, or unknown). Skinulceration status was not coded by SEER from 1983-1987; therefore, all 1983-1987 cases were coded as unknown for skin ulceration. 19 Five SEER variables, ''regional lymph node involvement' ' (1973-1982) , ''distant lymph nodes '' (1973-1982) , ''lymph nodes' ' (1983-2003) , and ''CS lymph nodes'' (2004), were recoded to categorize extent of lymph node involvement (none, regional, distant, or unknown).
Two surgical treatment variables were analyzed. Two SEER variables, ''site-specific surgery' ' (1973-1997) and ''surgery of the primary site' ' (1998-2004) , were recoded to form a dichotomous variable categorizing patients as receiving or not receiving any surgery on the primary site. Before 1983, type of surgery for melanoma was not recorded by SEER; therefore, patients diagnosed before 1983 were categorized as having ''no surgery'' (if the record indicated they did not have any surgery) or as ''surgery NOS,'' if the record indicated they received surgery). After 1982, type of surgery for melanoma was categorized as no surgery, biopsy, wide excision, amputation, and surgery NOS as recorded by the SEER registry (Appendix B).
Survival (in months) was calculated using date of diagnosis and one of the following: date of death, date last known to be alive, or cutoff date for this file (December 31, 2004) . The distributions of patient demographic and tumor-and treatment-related characteristics by race were compared by chi-square tests for categorical variables and analysis of variance for continuous variables. Two survival endpoints were examined: overall survival, defined as the time from diagnosis to death from any cause, and melanoma-specific survival, defined as the time from diagnosis to death from melanoma. Patients were stratified by receipt of surgery and by type of surgery to evaluate racial differences in survival after melanoma diagnosis. The Kaplan-Meier method was used to develop the survival curves, and the log-rank test was used to test for equality of survival curves. The Bonferroni correction for multiple comparisons was used in pairwise contrasts of the racial groups on the overall and melanoma-specific survival associated with receipt of surgery and with type of surgery. Cox proportional hazard regression models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of survival endpoints by race, for overall and melanoma-specific mortality risk, stratified by receipt of surgery and by surgery type; to assess differences in survival between each pair of racial groups, one set of models used ''whites'' as the reference group and another set of models used ''other race'' as the reference group. Each model was adjusted for age, sex, stage, anatomic site, histological subtype, tumor ulceration, presence of satellite nodules, lymph node involvement, and year of diagnosis. All analyses were conducted by SAS version 9.12 statistical software (SAS Institute, Cary, NC). Two-sided P values of \0.05 were considered statistically significant.
RESULTS
Demographic and clinical data for the study cohort are presented in Table 1 . Black patients were older at time of diagnosis. Tumor characteristics differed statistically significantly by race. Although 55.6% of all cases were diagnosed with local cutaneous melanoma and 29.6% with in situ melanoma, a larger proportion of black patients were diagnosed with regional (17.7%) and distant (10.4%) disease than patients who were white or other race. Melanomas were largely found on the trunk (31.1%), head and neck (23.1%), and upper limbs/shoulders (23.0%); but 51.7% of all melanomas in black patients were found on the lower extremities. Black patients were more likely to have been diagnosed with acral lentiginous melanoma, tumor ulcerations, satellite nodules, and positive lymph nodes in regional and distant areas.
Receipt of surgical treatment for melanoma and type of surgery also differed statistically significantly by race. Compared with patients who were white and other race, a larger percentage of black patients were not surgically treated for melanoma. Of those patients who received surgical treatment, blacks were more likely than the other two groups to undergo amputation. Of those 6265 patients who did not receive surgical treatment, 28.6% had distant disease. Demographic and clinical data stratified by type of surgery is displayed in Table 2 .
Median duration of follow-up for the entire cohort was 46 months (whites, 46; blacks, 40; and other race, 41). Of the 151,154 cutaneous melanoma cases, 30,339 (20%) died during follow-up. Of these deaths, 13,577 (44.8%) were due to melanoma. Cause of death was unknown in 1399 (4.6%) cases (4.6% white, 3.3% black, 5.6% other race). For the entire cohort, the 5-year and 10-year overall survival rates were 82.3% and 72.6%, respectively; the 5-year and 10-year melanoma-specific survival rates were 90.1% and 86.5%, respectively. Table 3 shows the 5-year and 10-year overall and melanoma-specific survival estimates by race, stratified by receipt of surgical treatment and by surgery type. Among patients who underwent surgery, 10-year overall and melanoma-specific survival rates were poorer for blacks than for whites and other race. Figure 1 presents the Kaplan-Meier curves for overall and melanoma-specific survival by race for patients who did and did not receive surgical treatment. Among patients who underwent any surgery, whites and other race had higher overall and melanoma-specific survival rates than blacks (P \ 0.0001).
Racial Differences in Survival by Receipt of Surgery
Multivariable Cox proportional hazard regression models were used to describe the association between race and risk of death during the study period while adjusting for demographic and tumor-related covariates. Table 4 shows the HR estimates of overall and melanoma-specific mortality by receipt of surgery. Among patients who did not receive surgical treatment, there were no statistically significant differences by race in risk of overall or melanomaspecific mortality. However, among patients who received surgical treatment, black patients were at significantly higher risk of overall and melanoma-specific mortality (HR = 1.64 and 1.50, respectively) when compared with white patients. In addition, after surgical treatment, black patients were at higher risk of overall (HR = 1.55, 95% CI 1.31-1.85, P \ 0.0001) and melanoma-specific mortality Table 4 ).
Differences in Survival by Type of Surgery
As shown in Table 3 , among patients who underwent wide excision of their primary melanoma or surgery NOS, blacks had statistically significantly worse overall and melanoma-specific survival compared to whites and other race (each P \ 0.02); overall and melanoma-specific survival was similar for whites and other race. There were no significant differences by race in overall and melanomaspecific survival among patients who had undergone amputation. Table 5 shows the HR estimates of overall and melanoma-specific mortality by surgery type. Blacks who underwent biopsy, wide excision or surgery NOS were at significantly higher risk of overall mortality when compared to whites with these same treatments, whereas risk of overall mortality was similar between patients who were white and other race with these same treatments. Blacks who underwent surgery NOS also were at significantly higher risk of melanoma-specific mortality when compared to whites with the same treatment. In addition, blacks were at higher risk of overall mortality after wide excision (HR = 1.72, 95% CI 1.28-2.30, P = 0.0003) or surgery NOS (HR = 1.74, 95% CI, 1.29-2.33, P = 0.0003) and were at higher risk of melanoma-specific mortality after surgery NOS (HR = 1.70, 95% CI 1.16-2.50, P = 0.0065) when compared to other race with the same treatment (data not shown in Table 5 ).
DISCUSSION
Although cutaneous melanoma is rare among racial/ ethnic minorities, studies indicate that blacks are at an increased risk of dying from melanoma compared with whites. [4] [5] [6] 8, 20, 21 Several factors have been studied in relation to higher cancer-related mortality rates among racial/ ethnic minorities, including lower socioeconomic status, access to health care, more advanced stage at diagnosis, differences in tumor biology, and in treatment. 1, 8, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Such studies, however, have been limited by the small numbers of minority patients analyzed. The large number of patients captured in the SEER database allowed for sufficient statistical power for the analyses reported herein. In this population-based study, racial/ethnic differences in overall and melanoma-specific survival were examined, comparing patients who did and did not receive surgical treatment and patients who received different types of surgical treatment. When blacks underwent surgical treatment for melanoma, they had shorter survival compared with whites and other race (Table 3 ) and were at greater risk of death after controlling for demographic and tumorrelated characteristics (Table 4) . Among patients who did not undergo surgery, however, neither risk of overall nor melanoma-specific mortality differed statistically significantly by race. Black patients were less likely to have received surgery for melanoma. All patients who did not receive surgery were more likely to be diagnosed with distant disease.
Melanoma in black patients might follow a different, more aggressive course than in white patients. Blacks were more likely than whites to have acral lentiginous melanoma. Acral lentiginous melanoma, unlike other melanoma subtypes, is found on non-sun-exposed palmoplantar surfaces, with a higher incidence in persons of color, especially black patients. This tumor subtype is associated with lower overall survival rates in minority populations and is associated with such factors as increased tumor thickness and advanced stage at presentation. 7,37-39 Black patients were more likely to be diagnosed at more advanced stages of disease compared with whites, as reported elsewhere, and were more likely to have tumor ulceration, satellite nodules and regional and distant These findings emphasize the importance of trying to detect a patient's cutaneous melanoma earlier, when it is smaller and less invasive, leading to a greater chance of survival. Our study and others that included race, histological subtype, and stage in their multivariable models observed an elevated risk of death from melanoma for black compared to white patients. 4, 8 Studies that reported on increasing melanoma incidence rates in white Hispanic populations and advanced stage at presentation in blacks and Hispanics suggest that unmeasured factors such as socioeconomic status, skin cancer awareness and cultural and social values affect melanoma stage at diagnosis. 2, 3, 40 However, these studies did not examine mortality rates in these minority racial/ethnic groups. Poorer outcomes for black patients with melanoma, in particular, may have several explanations. First, melanoma tumors may be biologically different and/or more aggressive in blacks. The molecular or genetic mechanisms underlying potential differences in tumor biology among people of different races have not been determined. If such differences exist, they could have profound implications for the treatment of melanoma in different racial groups, such as a lower threshold for performing sentinel lymph node or complete lymph node dissection or use of different systemic therapies. 45 Alternatively, some nonwhite patients with melanoma might have lower access to care and experience disparities in receipt of other treatments not included in the SEER registry. However, a California Cancer Registry study that included a small sample of 127 black patients and receipt of surgical treatment in their analysis as well as receipt of chemotherapy, radiotherapy, and immunotherapy observed poorer overall survival in black patients that was not explained by differences in treatment or socioeconomic status. 8 Also, much like the public-access SEER database, the California Cancer Registry does not include information about comorbidity, insurance status or date of recurrence, all of which have prognostic significance.
The SEER data are further limited by lack of data regarding nonsurgical treatment for melanoma, such as chemotherapy and biologic therapy, as well as data on psychosocial factors, margin status of biopsies, location of distant metastases, and recurrence, all of which might increase one's mortality risk. Because of inconsistencies in the data recorded by SEER registries over the study period, we were not able to analyze the data by some known prognostic factors, such as tumor thickness and American Joint Committee on Cancer staging. Although it has been indicated that black patients in particular have lower overall and melanoma-specific survival, the potential impact of these unmeasured variables on survival could not be assessed. 4, 7, 8, 20, 21, 38, [41] [42] [43] [44] 46 Population-based, retrospective cohort studies that use these publicly available 60  120  180  240  300  360  60  120  180  240  300  360   60  120  180  240  300  360  60  120  180  240  300  360 FIG. 1 Kaplan-Meier analyses indicating differences in overall and melanoma-specific survival between patients who had surgery and patients who did not have surgery stratified by race. P values are log-rank tests.
Overall survival: surgery, P \ 0.0001; no surgery, P = 0.1405. Melanoma-specific survival: surgery, P \ 0.0001; no surgery, P = 0.2595 large databases are limited to some extent by lack of data about potential confounders. There also may be some limitations in generalizability of our findings as a result of selection bias because SEER registries are more likely to sample from urban than from rural areas. 47 Finally, causal inferences from the associations we observed cannot be made. However, these findings can direct future research to determine the cause(s) of poorer outcomes in minority patients with melanoma.
Despite the limitations of this study, to our knowledge, this is the first study that uses the high-quality, populationbased SEER data to demonstrate poorer survival outcomes for black patients with melanoma not only by receipt of surgical treatment but by type of surgical treatment. 15 In conclusion, melanoma in black patients appears to have characteristics which require a different or more aggressive approach to treatment than in white patients. Certain tumor-biology or genetic characteristics may be implicit in melanoma in people of color, which is feasible given the higher concentrations of melanocytes and pigment in minority populations. Differences in tumor characteristics may lead to a different mechanism of tumor genesis, and in turn to different patterns of tumor growth and rates of metastases. Improving our understanding of these differences could have profound treatment and population-level public health implications. 45, 48 Given the low overall incidence of melanoma among African Americans, large population-based, observational studies such as this one can help us understand the relationships between various clinical and treatment factors and melanoma outcomes in black patients. However, future prospective studies aimed at discovering the biologic and/or genetic characteristics of melanoma tumors in this population are warranted to improve survival for black patients with melanoma. 
